-
1.发明公开
公开(公告)号：EP4324472A3
公开(公告)日：2024-08-28
申请号：EP23216403.8
申请日：2016-08-05
发明人： Mahr, Andrea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet , Müller, Phillip , Leibold, Julia , Goldfinger, Valentina
IPC分类号： C07K7/06 , C07K14/47 , A61K39/00 , A61P35/00 , C07K14/725 , A61K38/00 , C12N9/64 , C12N5/0783 , C12N5/0784
CPC分类号： C07K14/4748 , C12N2310/1620130101 , A61K38/00 , A61K39/0011 , C07K14/7051 , C07K2319/0020130101 , A61P35/00 , C07K7/06 , A61K39/4611 , C12N5/0639 , C12N5/0636 , A61K39/4644 , C12N9/6445
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumorassociated T-cell peptide epitopes, alone or in combination with other tumorassociated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：EP3980776B1
公开(公告)日：2024-08-28
申请号：EP20731438.6
申请日：2020-06-04
IPC分类号： A61K35/76 , G01N33/554 , G01N15/10 , C12N5/0783 , G01N15/14 , A61K35/17
-
公开(公告)号：EP3388078B1
公开(公告)日：2024-05-29
申请号：EP18174323.8
申请日：2016-03-24
CPC分类号： A61K38/00 , C07K14/70539 , A61K39/0011 , C07K14/7051 , C07K14/4748 , C07K2319/0020130101 , C07K14/47 , C07K2319/4020130101 , C07K14/4702 , C12N9/6491 , C12Y304/24 , A61P35/00 , A61P35/02 , A61P39/00 , A61K38/08 , A01N37/46 , A61K31/404 , A61K31/4745 , A61K31/519 , A61K31/675 , A61K38/06 , A61K38/1774 , A61K39/001102 , A61K39/001103 , A61K39/001148 , A61K39/001152 , A61K39/001154 , A61K39/001159 , A61K39/001162 , A61K39/001184 , A61K45/06 , A61K2039/5420130101 , A61K2039/5720130101 , A61K2039/57220130101 , A61K2039/58520130101 , A61P37/04 , A61P43/00 , C07K2319/5520130101 , C07K2319/6020130101 , C12N5/0093 , C12N5/0636 , C12N5/0693 , C12N2510/0020130101 , A61K39/4611 , C12N5/0646 , A61K39/4644 , C12N5/0638 , A61K39/00
-
4.发明授权
公开(公告)号：EP3430027B1
公开(公告)日：2023-09-13
申请号：EP17710904.8
申请日：2017-03-15
发明人： MAHR, Andrea , SCHOOR, Oliver , WEINSCHENK, Toni
-
公开(公告)号：EP3430037B1
公开(公告)日：2022-08-31
申请号：EP17710963.4
申请日：2017-03-16
发明人： MAURER, Dominik , ALTEN, Leonie , BUNK, Sebastian
IPC分类号： C07K14/725 , A61K39/00 , C07K14/74 , C12N5/0783
-
公开(公告)号：EP3456339B1
公开(公告)日：2021-10-20
申请号：EP18201334.2
申请日：2014-08-04
IPC分类号： A61K38/17 , A61K39/00 , C07K7/06 , C12N5/0783
-
-
8.发明公开
公开(公告)号：EP3712165A3
公开(公告)日：2020-12-02
申请号：EP20170129.9
申请日：2016-06-29
发明人： MAHR, Andrea , WEINSCHENK, Toni , HÖRZER, Helen , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet
摘要： Provided is a peptide of up to 30 amino acids comprising the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 1 or SEQ ID NO: 2, or one of SEQ ID NO: 4 to SEQ ID NO: 10 or SEQ ID NO: 12 to SEQ ID NO: 640. Provided are inter alia also a nucleic acid encoding such peptide, a host cell comprising the same, a T-cell receptor reactive with such peptide and an activated T lymphocyte recognizing a cell which presents such peptide. Provided is also the use of any of the above in cancer treatment.
-
9.发明公开
公开(公告)号：EP3708185A2
公开(公告)日：2020-09-16
申请号：EP20170980.5
申请日：2015-06-17
摘要： Provided are peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. Provided are also tumor-associated cytotoxic T cell (CTL) peptide epitopes that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. Provided are several peptide sequences derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：EP3120869B1
公开(公告)日：2020-07-22
申请号：EP16179192.6
申请日：2009-09-28
-
-
-
-
-
-
-
-
-
搜索结果
268 条记录 (耗时 0.035 秒)
